UK agency says Pfizer breast cancer drug too expensive

LONDON (Reuters) - Pfizer's breast cancer drug Ibrance, or palbociclib, is too expensive to justify its use on Britain's state-run health service, the country's healthcare cost-effectiveness watchdog said on Friday.

The National Institute for Health and Care Excellence (NICE) said in draft guidance that although the medicine was likely to offer some improvement in overall survival, this could not be quantified from clinical trials.

"Even when allowing for these potential benefits, it was still not enough to make palbociclib cost effective at its current price," Carole Longson, director of NICE's center for health technology assessment, said in a statement on Friday.

Ibrance's list price is 2,950 pounds ($3,700) per 28 days.

Pfizer UK's oncology head David Montgomery noted that the NICE decision was not final decision and said the U.S. drugmaker was committed to working to try and find a solution to make the drug available.

(Reporting by Ben Hirschler, editing by Pritha Sarkar)

Must Read

Fidel Castro thanks Cuba, criticizes Obama, on 90th birthday

Aug 14, 2016

Fidel Castro thanked Cubans for their well-wishes on his 90th birthday and criticized President Barack Obama in a lengthy letter published in state media

Asian stocks drift pending fresh news; oil takes a breather

Aug 16, 2016

Asian stock markets drifted sideways on Tuesday as the price of oil took a breather from a three-day rally

Bolt advances, Russian qualifies and an engagement at track

Aug 17, 2016

The midpoint of the nine-day track and field program at Olympic Stadium was a day for diamond rings and making friends, a rare Russian hello and a surprising Brazilian farewell

Search

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales[at]obserworld.com